Takayasu Arteritis
1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
UNION therapeuticsDenmark - Hellerup
2 programs1
MMFPhase 31 trial
Pulmonary Artery Involvement in Takayasu's ArteritisN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
UNION therapeuticsMMF
Chugai PharmaTocilizumab
UNION therapeuticsPulmonary Artery Involvement in Takayasu's Arteritis
Clinical Trials (3)
Total enrollment: 207 patients across 3 trials
Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis
Start: Mar 2017Est. completion: Nov 2022138 patients
Phase 3Completed
Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis
Start: Jun 2014Est. completion: Feb 201918 patients
Phase 3Completed
Pulmonary Artery Involvement in Takayasu's Arteritis
Start: Jan 2014Est. completion: Dec 201551 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.